Revenue91011128$1.1B in 2025+216% since 2019Gross profit1391011$684.8M in 2023+109% since 2019Operating income91011128$104.8M in 2025Net income91011128$391.0M in 2025
Revenue1415$308.0M in Q2 FY2026+15% since Q1 FY2026Operating income1415$37.8M in Q2 FY2026Net income1415$31.5M in Q2 FY2026+766% since Q1 FY2026
Every line of the income statement as filed: the last 3 fiscal years, latest first.8
Period ending
2025-12-31
2024-12-31
2023-12-31
Total revenues
$1.1B
$957.8M
$726.4M
Cost of product sales
$89.0M
$81.8M
$41.6M
Research and development
$328.8M
$303.2M
$351.6M
Selling, general and administrative
$548.9M
$488.4M
$406.6M
Gain on sale of non-financial asset
$0
-$146.5M
$0
Total operating expenses
$966.7M
$727.0M
$799.8M
Income (loss) from operations
$104.8M
$230.8M
-$73.4M
Interest income, net
$31.7M
$25.5M
$17.2M
Other income
$2.4M
$1.8M
$5.1M
Income (loss) before income taxes
$138.9M
$258.1M
-$51.0M
Income tax (benefit) expense
-$252.1M
$31.6M
$10.2M
Consolidated net income
$391.0M
$226.5M
-$61.3M
Earnings (net loss) per share, Basic
$2.32
$1.37
-$0.37
Earnings (net loss) per share, diluted
$2.30
$1.36
-$0.37
Weighted average common shares outstanding, basic
168.4M shares
165.7M shares
163.8M shares
Weighted average common shares outstanding, diluted
169.9M shares
166.4M shares
163.8M shares
No quarter-by-quarter statement was filed.
Total assets1391011128$1.6B in 2025+100% since 2019Total liabilities1391011128$336.8M in 2025+301% since 2019Shareholders’ equity1011128$1.2B in 2025+76% since 2019Cash91011128$177.7M in 2025−6% since 2019
Total assets1415$1.7B in Q2 FY2026+11% since Q1 FY2025Total liabilities1415$436.3M in Q2 FY2026+30% since Q1 FY2025Shareholders’ equity1415$1.3B in Q2 FY2026+6% since Q1 FY2025Cash1415$385.0M in Q2 FY2026+117% since Q1 FY2025
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.8
Period ending
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Cash and cash equivalents
$177.7M
$319.6M
$188.7M
Investment securities, available-for-sale
$642.0M
$436.4M
Accounts receivable, net
$121.5M
$98.7M
Interest and other receivables
$26.8M
$6.0M
Inventory
$34.7M
$21.9M
Prepaid expenses
$59.5M
$55.7M
Total current assets
$1.1B
$938.3M
Property and equipment, net
$7.5M
$4.2M
Operating lease right-of-use assets
$47.4M
$46.6M
Intangible assets, net
$108.9M
$119.8M
Restricted cash
$7.8M
$8.8M
$5.8M
Long-term inventory
$76.7M
$69.7M
Deferred tax assets
$249.9M
$0
Other assets
$3.9M
$359.0K
Total assets
$1.6B
$1.2B
Accounts payable
$10.9M
$16.2M
Accrued liabilities
$266.2M
$378.7M
Total current liabilities
$277.1M
$394.9M
Operating lease liabilities
$40.6M
$42.0M
Other long-term liabilities
$19.1M
$18.1M
Total liabilities
$336.8M
$455.0M
Preferred stock, $0.0001 par value; 5,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024
$0
$0
Common stock, $0.0001 par value; 225,000,000 shares authorized at December 31, 2025 and 2024; 170,309,376 shares and 166,708,856 shares issued and outstanding at December 31, 2025 and 2024, respectively
$16.0K
$16.0K
Additional paid-in capital
$3.0B
$2.9B
Accumulated deficit
-$1.8B
-$2.2B
Accumulated other comprehensive income
$1.4M
$292.0K
Total stockholders equity
$1.2B
$732.8M
$431.8M
$400.4M
Total liabilities and stockholders equity
$1.6B
$1.2B
Preferred stock, par value
$0.00
$0.00
Preferred stock, shares authorized
5.0M shares
5.0M shares
Preferred stock, shares issued
0 shares
0 shares
Preferred stock, shares outstanding
0 shares
0 shares
Common stock, par value
$0.00
$0.00
Common stock, shares authorized
225.0M shares
225.0M shares
Common stock, shares issued
170.3M shares
166.7M shares
Common stock, shares outstanding
170.3M shares
166.7M shares
Period ending
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Cash and cash equivalents
$177.7M
$319.6M
$188.7M
Investment securities, available-for-sale
$642.0M
$436.4M
Accounts receivable, net
$121.5M
$98.7M
Interest and other receivables
$26.8M
$6.0M
Inventory
$34.7M
$21.9M
Prepaid expenses
$59.5M
$55.7M
Total current assets
$1.1B
$938.3M
Property and equipment, net
$7.5M
$4.2M
Operating lease right-of-use assets
$47.4M
$46.6M
Intangible assets, net
$108.9M
$119.8M
Restricted cash
$7.8M
$8.8M
$5.8M
Long-term inventory
$76.7M
$69.7M
Deferred tax assets
$249.9M
$0
Other assets
$3.9M
$359.0K
Total assets
$1.6B
$1.2B
Accounts payable
$10.9M
$16.2M
Accrued liabilities
$266.2M
$378.7M
Total current liabilities
$277.1M
$394.9M
Operating lease liabilities
$40.6M
$42.0M
Other long-term liabilities
$19.1M
$18.1M
Total liabilities
$336.8M
$455.0M
Preferred stock, $0.0001 par value; 5,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024
$0
$0
Common stock, $0.0001 par value; 225,000,000 shares authorized at December 31, 2025 and 2024; 170,309,376 shares and 166,708,856 shares issued and outstanding at December 31, 2025 and 2024, respectively
$16.0K
$16.0K
Additional paid-in capital
$3.0B
$2.9B
Accumulated deficit
-$1.8B
-$2.2B
Accumulated other comprehensive income
$1.4M
$292.0K
Total stockholders equity
$1.2B
$732.8M
$431.8M
$400.4M
Total liabilities and stockholders equity
$1.6B
$1.2B
Preferred stock, par value
$0.00
$0.00
Preferred stock, shares authorized
5.0M shares
5.0M shares
Preferred stock, shares issued
0 shares
0 shares
Preferred stock, shares outstanding
0 shares
0 shares
Common stock, par value
$0.00
$0.00
Common stock, shares authorized
225.0M shares
225.0M shares
Common stock, shares issued
170.3M shares
166.7M shares
Common stock, shares outstanding
170.3M shares
166.7M shares
Cash from operations91011128$109.8M in 2025Capital spending91011128$4.7M in 2025+315% since 2019Free cash flow91011128$105.1M in 2025
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.8
Period ending
2025-12-31
2024-12-31
2023-12-31
Net income (loss)
$391.0M
$226.5M
-$61.3M
Stock-based compensation
$52.1M
$67.0M
$66.4M
Amortization of premiums and accretion of discounts on investment securities
-$5.4M
-$9.3M
-$7.5M
Amortization of intangible assets
$10.9M
$15.0M
$4.1M
Gain on sale of non-financial asset
$0
-$146.5M
$0
Gain on strategic investment
$0
$0
-$5.1M
Depreciation
$871.0K
$920.0K
$1.5M
Loss on sale of investment securities
$0
$0
$524.0K
Deferred income taxes (including benefit from valuation allowance)
-$249.9M
$0
$0
Accounts receivable, net
-$22.7M
-$472.0K
-$36.1M
Interest and other receivables
-$20.8M
-$1.9M
-$3.2M
Inventory
-$18.2M
-$49.5M
-$28.8M
Prepaid expenses and other current assets
-$3.8M
-$16.6M
-$17.7M
Operating lease right-of-use assets
$8.7M
$7.5M
$5.8M
Other assets
-$2.9M
$117.0K
-$33.0K
Accounts payable
-$5.3M
-$1.4M
$4.8M
Accrued liabilities
-$19.3M
$71.1M
$93.2M
Operating lease liabilities
-$6.5M
-$7.6M
-$5.9M
Long-term liabilities
$1.1M
$2.9M
$6.1M
Net cash provided by operating activities
$109.8M
$157.7M
$16.7M
Purchases of investment securities
-$692.6M
-$505.1M
-$370.0M
Sale and maturity of investment securities
$493.5M
$328.6M
$429.8M
Proceeds from sale of non-financial asset
$0
$146.5M
$0
Proceeds from sales of strategic investment
$0
$0
$12.3M
Net purchases of property and equipment
-$4.7M
-$523.0K
-$50.0K
Payment of milestone and contingent payments in connection with asset acquisition
-$98.8M
$0
-$40.0M
Net cash (used in) provided by investing activities
-$302.6M
-$30.5M
$32.0M
Proceeds from issuance of common stock, net of issuance costs
$49.9M
$6.8M
$25.1M
Net cash provided by financing activities
$49.9M
$6.8M
$25.1M
Effect of exchange rate changes on cash
$26.0K
-$94.0K
-$18.0K
Net (decrease) increase in cash, cash equivalents and restricted cash
-$142.8M
$133.9M
$73.8M
Cash paid for income taxes
$25.2M
$19.5M
$5.8M
Accrued inventory purchases
$1.2M
$1.3M
$0
Stock based compensation capitalized
$426.0K
$425.0K
$79.0K
Accrued milestone and contingent payments in connection with asset acquisition
Acadia Pharmaceuticals sits at the top of its group. 13 entities, 9 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Acadia Pharmaceuticals GmbH Acadia Pharmaceuticals Holdings Inc. Acadia Pharmaceuticals (Canada) Inc. Subsidiary · Canada
Amorsa Therapeutics Inc. Subsidiary · Massachusetts, United States
CerSci Therapeutics Incorporated Subsidiary · Delaware, United States
Levo Therapeutics, Inc. Subsidiary · Delaware, United States
Pandeia Therapeutics Limited Subsidiary · United Kingdom
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Acadia Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
As of December 31, 2025, our primary facility consists of approximately 67,000 square feet of office space in San Diego, California, pursuant to a lease that expires in May 2031. We also lease a facility in Princeton, New Jersey that covers approximately 25,000 square feet of office space, which is leased on a month-to-month basis after it expired in January 2026. In addition, we lease a new facility in Princeton, New Jersey that covers approximately 53,000 square feet of office space, which is expected to commence in the second quarter of 2026. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.
Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. In 1997, the company relocated all operations and management from Vermont to San Diego, California, as a strategic move to garner partnerships with other biotechnology companies. However, the company also had an office in Denmark, in which it received a crucial part of its early investments from BankInvest, under managing director Florian Schönharting, Kommunernes Pensionsforsikring A/S and Dansk Kapitalanlæg Aktieselskab as well as private investor Lars Christiansen. At the time, the company had fifty employees, fourteen of whom were in the Denmark office. The focus of the company in its early years was on genetic screens for receptors, aiming to accelerate early stage drug discovery.
The company planned to conduct an initial public offering (IPO) consisting of 31.6% of the company in 2001, with the intention of raising US$64 million and listing on the NASDAQ exchange under the symbol ACAD. At the time, Acadia and Allergan were collaborating on development of a treatment for glaucoma, and Allergan would retain a 6.3% ownership stake in Acadia after the IPO. However, the company's IPO, which ultimately took place in May 2004, did not fare as well as expected and netted only US$35 million. At the time, the company had five drugs in development and was running two in human trials. The company had a subsequent round of stock offering in May 2007 which raised US$102 million.
In September 2020, Acadia Pharmaceuticals acquired clinical-stage biotechnology company CerSci Therapeutics.
Corporate governance
In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.
Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning." On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors. Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009.
Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia-related psychosis, major depressive disorder, schizophrenia inadequate response, and schizophrenia negative symptoms.
As of 1997, Acadia was among several companies that licensed compounds from Genzyme's small-molecule compound library.
In 2023, the FDA approved trofinetide (marketed as Daybue) for use in Rett syndrome.
Feb 26, 2025Reported quarterly or annual results66
Drug trials and FDA: coming up
Aug 2027Phase 2 trial readout expected Phase 2 trial of ACP-211 in Major Depressive Disorder (MDD): primary completion expected Aug 2027 (ClinicalTrials.gov NCT07284667).67
Drug trials and FDA: recently
Apr 27, 2026FDA approved a new use FDA approved an efficacy supplement for Nuplazid (pimavanserin tartrate), a new use or patient group (NDA 207318, supplement 16).68
Mar 27, 2026FDA approved a new use FDA approved an efficacy supplement for Daybue (trofinetide), a new use or patient group (NDA 217026, supplement 8).69
Dec 11, 2025FDA approval FDA approved Daybue Stix (trofinetide), orphan drug (NDA 219884).70
Aug 19, 2025Phase 3 trial completed Phase 3 trial of Carbetocin in Hyperphagia in Prader-Willi Syndrome: primary completion Aug 19, 2025, results posted Oct 15, 2026 (ClinicalTrials.gov NCT06173531).71
Sep 30, 2024FDA approved a new use FDA approved an efficacy supplement for Daybue (trofinetide), a new use or patient group (NDA 217026, supplement 1).72
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Filings
338 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 49 major events, 192 insider forms, 22 large holders, 55 other. The latest 20:
120 open-market trades by officers, directors and large owners since October 2021: 3 buys and 117 sales. Grants, option exercises and gifts are left out.
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Acadia Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).16
Risk factors and legal proceedings
The risks Acadia Pharmaceuticals names in Item 1A of its 10-K filed Feb 26, 2026: 48 risks under these headings, as written.16
You should consider carefully the following information about the risks described below, together with the other information contained in this Annual Report and in our other public filings, in evaluating our business. If any of the following risks actually occurs, our business, financial condition, results of operations, and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline.
Risks Related to Our Products and Product Candidates
Our prospects are highly dependent on the successful commercialization of our products. To the extent we cannot establish, maintain or increase sales of our products, our business, financial condition and results of operations may be materially adversely affected and the price of our common stock may decline.
Our products may not gain maximal acceptance among physicians, patients, caregivers and the medical community, thereby limiting our potential to generate revenues.
Our ability to generate product revenues will be diminished if coverage for our products from commercial or government payors is not provided, is decreased or if patients have unacceptably high out-of-pocket requirements.
Our products are subject to ongoing regulatory requirements that could cause us significant expense and delay or limit our ability to generate sales revenues.
We rely on a limited network of third-party distributors and pharmacies to market and sell our products. If this approach ceases to be effective, commercialization of our products may be adversely affected, and our products may not be profitable.
Drug development is a long, expensive and unpredictable process with a high risk of failure, and there is no guarantee that our products or product candidates will be successful in ongoing or future clinical trials or obtain regulatory approval.
The regulatory approval processes in the EU and outside North America are lengthy, time consuming and inherently unpredictable, and if we do not obtain regulatory approval of trofinetide outside North America, we will not be able to market trofinetide outside North America, which will limit our trofinetide commercial revenues.
Expanded access or compassionate use programs could subject us to additional risks.
Delays, suspensions, variations and terminations in our clinical trials for our product candidates could result in increased costs to us and delay our ability to generate product revenues.
If we are unable to attract, retain, and motivate key management, research and development, and sales and marketing personnel, our drug development programs, our research and discovery efforts, and our commercialization plans may be delayed and we may be unable to successfully commercialize our products, or develop our product candidates.
The other 37 risks
Risks Related to Our Business
If we fail to develop, acquire or in-license other product candidates or products, our business and prospects would be limited. Even if we obtain rights to other product candidates or products, we will incur a variety of costs and may never realize the anticipated benefits.
We may require additional financing in the future to fund our operations. If we cannot raise additional financing in the future, we may be unable to fund our business plan and our future research, development, commercial and manufacturing efforts.
We expect that our results of operations will fluctuate, which may make it difficult to predict our future performance from period to period.
Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.
Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited.
Tax authorities could reallocate our taxable income among our subsidiaries, which could increase our overall tax liability.
Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
We or the third parties upon whom we depend may be adversely affected by catastrophic events, such as earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
We have incurred, and expect to continue to incur, significant costs as a result of laws, regulations and standards relating to various aspects of our business, including corporate governance, work force initiatives and other matters, and failure to comply with such laws, regulations and standards could adversely affect our business.
Our business involves the use of hazardous materials, and we and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business.
Our management has broad discretion over the use of our cash and we may not use our cash effectively, which could adversely affect our results of operations.
Risks Related to Our Relationships with Third Parties
We depend on collaborations with third parties to develop certain of our product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.
Our collaborations may be subject to conflicts or disputes, which could have a material adverse effect on our business, results of operations and financial condition.
We rely on third parties to conduct our clinical trials and perform data collection and analysis, which may result in costs and delays that prevent us from successfully commercializing product candidates, if approved.
We currently depend, and in the future will continue to depend, on third parties to manufacture our products and product candidates. If these manufacturers fail to provide us or our collaborators with adequate supplies of clinical trial materials and commercial product or fail to comply with the requirements of regulatory authorities, we may be unable to develop or commercialize our products or product candidates, if approved.
We may not be able to continue or fully exploit our collaborations with outside scientific and clinical advisors, which could impair the progress of our clinical trials and our research and development efforts.
Risks Related to Our Intellectual Property
Our ability to compete may decline if we do not adequately protect our proprietary rights.
Confidentiality agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete.
A dispute concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time-consuming and costly, and an unfavorable outcome could harm our business.
The patent applications of pharmaceutical and biotechnology companies involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position.
Risks Related to Government Regulation and Our Industry
Healthcare reform measures may negatively impact our ability to sell NUPLAZID, DAYBUE or our product candidates, if approved, profitably.
We are subject, directly and indirectly, to federal, state and foreign healthcare laws and regulations, including healthcare fraud and abuse laws, false claims laws, physician payment transparency laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.
If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, fines, sanctions and exposure under other laws which could have a material adverse effect on our business, results of operations and financial condition.
We could face liability if a regulatory authority determines that we are promoting our products for any “off-label” uses.
Changes at the FDA and other government agencies could delay or prevent new products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
We are subject to stringent regulation in connection with the marketing of our products, which could delay the development, approval and commercialization of our products.
If our competitors develop and market products that are more effective than our products, they may reduce or eliminate our commercial opportunity.
If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products, or development or commercialization of our product candidates, if approved.
If our information technology systems or data, or those of third parties with whom we work, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, interruptions to operations or clinical trials, reputational harm, litigation, fines and penalties, disruptions of our business operations, and a loss of customers or sales.
Risks Related to Our Common Stock
Our stock price historically has been, and is likely to remain, highly volatile.
If we or our stockholders sell substantial amounts of our common stock, the market price of our common stock may decline.
If our officers, directors, and largest stockholders choose to act together, they may be able to significantly influence our management and operations, acting in their best interests and not necessarily those of our other stockholders.
Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us more complicated and may make the removal and replacement of our directors and management more difficult.
Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
We do not intend to pay dividends on our common stock in the foreseeable future; as such, you must rely on stock appreciation for any return on your investment.
Legal proceedings
Patent Infringement
On July 24, 2020, we filed complaints against (i) Aurobindo Pharma Limited and its affiliate Aurobindo Pharma USA, Inc. and (ii) Teva Pharmaceuticals USA, Inc. and its affiliate Teva Pharmaceutical Industries Ltd., and on July 30, 2020, we filed complaints against (i) Hetero Labs Limited and its affiliates Hetero Labs Limited Unit-V and Hetero USA Inc., (ii) MSN Laboratories Private Ltd. and its affiliate MSN Pharmaceuticals, Inc., and (iii) Zydus Pharmaceuticals (USA) Inc. and its affiliate Cadila Healthcare Limited. These complaints, which were filed in the United States District Court for the District of Delaware, allege infringement of certain of our Orange Book-listed patents covering NUPLAZID (Pimavanserin I Cases).
We entered into an agreement effective April 22, 2021 with Hetero settling all claims and counterclaims in the litigation. The agreement allows Hetero to launch its generic pimavanserin product on February 27, 2038, subject to certain triggers for earlier launch. The Hetero case was dismissed by joint agreement on May 3, 2021.
On September 30, 2022, we filed a stipulation and proposed order to stay the claims currently asserted against Teva and for Teva to be bound by the result of the litigation rendered against the remaining defendants Aurobindo and MSN, which was ordered by the Court on October 4, 2022.
